PTAB Denies Inter Partes Review of Rituxan® Patents

The Patent Trial and Appeal Board (“the Board”) has decided not to institute inter partes review (“IPR”) on two patents owned by Biogen and Genentech. Pfizer, Inc. (“Pfizer”) filed two petitions asserting that the patents, U.S. Patent Nos. 8,206,711 (“the ’711 patent”) and 7,682,612 (“the ’612 patent”), were invalid as obvious in view of prior art. Both of these patents relate to Rituxan® (rituximab) and its use in the treatment of chronic lymphocytic leukemia (“CLL”).

https://www.lexology.com/library/detail.aspx?g=104d650d-3eb7-4487-af46-ad466ca91ee7